Cipla stock benefits from new drug for malaria
DSIJ Intelligence / 26 Jul 2017
Cipla, a pharmaceutical player, and its product development partner, Medicines for Malaria Venture (MMV), today announced the launch of a life-saving, pre-referral intervention for the management of severe malaria in young children.
Cipla, a pharmaceutical player, and its product development partner, Medicines for Malaria Venture (MMV), today announced the launch of a life-saving, pre-referral intervention for the management of severe malaria in young children. This is the 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS).
Initially developed by the World Health Organization’s (WHO) Tropical Diseases Research Programme, RAS 100 mg was recently added to the Global Fund Expert Review Panel’s list of quality-assured medicines, while the process of WHO pre-qualification of this medicine moves through its final stages. This authorisation makes it the first quality-assured RAS product.
Meanwhile, the stock gained 1.25% at Rs 571.55 per share on BSE. On NSE, the stock attracted a traded volume of 6,38,434 shares and a traded value of Rs 3,628.92 lakh. The company has a return of equity of 10% for the last three years. The dividend payout of the company is 4.53% of profits over the last three years.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.